Cottontail rabbit papillomavirus (CRPV) model system to test antiviral and immunotherapeutic strategies

Research output: Contribution to journalReview article

40 Citations (Scopus)

Abstract

The cottontail rabbit papillomavirus (CRPV)/rabbit model has proven to be the most versatile preclinical model to test antiviral, immunopotentiating and immunotherapeutic strategies for papilloma-virus infections. We have utilized this model for many years and have recently observed significant improvements in the utility of the model. Improvements have included various techniques to infect rabbit skin sites with strains of wild-type and mutant CRPV DNA prepared using standard molecular biological procedures. A better understanding of the virus life cycle in vivo has been gained also from these studies such that we now have several defined strains of CRPV including i) antigenically diverse strains of CRPV, ii) mutant strains of CRPV with reduced growth rates, and iii) mutant strains of CRPV that demonstrate accelerated malignant progression rates. Collectively, these mutant genomes provide laboratories with a powerful pre-clinical model to assess a variety of antiviral therapies. Many of the treatments already tested in the CRPV/rabbit model have shown parallel efficacy against HPV infections in a clinical setting. Some of our recent experiences with the CRPV/rabbit model are outlined in this brief overview.

Original languageEnglish (US)
Pages (from-to)355-362
Number of pages8
JournalAntiviral Chemistry and Chemotherapy
Volume16
Issue number6
DOIs
StatePublished - Jan 1 2005

Fingerprint

Cottontail rabbit papillomavirus
Antiviral Agents
Rabbits
Papilloma
Virus Diseases
Life Cycle Stages
Genome
Viruses

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery
  • Virology

Cite this

@article{4d2def1aa04f45c2b29df4426bba5c34,
title = "Cottontail rabbit papillomavirus (CRPV) model system to test antiviral and immunotherapeutic strategies",
abstract = "The cottontail rabbit papillomavirus (CRPV)/rabbit model has proven to be the most versatile preclinical model to test antiviral, immunopotentiating and immunotherapeutic strategies for papilloma-virus infections. We have utilized this model for many years and have recently observed significant improvements in the utility of the model. Improvements have included various techniques to infect rabbit skin sites with strains of wild-type and mutant CRPV DNA prepared using standard molecular biological procedures. A better understanding of the virus life cycle in vivo has been gained also from these studies such that we now have several defined strains of CRPV including i) antigenically diverse strains of CRPV, ii) mutant strains of CRPV with reduced growth rates, and iii) mutant strains of CRPV that demonstrate accelerated malignant progression rates. Collectively, these mutant genomes provide laboratories with a powerful pre-clinical model to assess a variety of antiviral therapies. Many of the treatments already tested in the CRPV/rabbit model have shown parallel efficacy against HPV infections in a clinical setting. Some of our recent experiences with the CRPV/rabbit model are outlined in this brief overview.",
author = "Neil Christensen",
year = "2005",
month = "1",
day = "1",
doi = "10.1177/095632020501600602",
language = "English (US)",
volume = "16",
pages = "355--362",
journal = "Antiviral Chemistry and Chemotherapy",
issn = "0956-3202",
publisher = "International Medical Press Ltd",
number = "6",

}

Cottontail rabbit papillomavirus (CRPV) model system to test antiviral and immunotherapeutic strategies. / Christensen, Neil.

In: Antiviral Chemistry and Chemotherapy, Vol. 16, No. 6, 01.01.2005, p. 355-362.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Cottontail rabbit papillomavirus (CRPV) model system to test antiviral and immunotherapeutic strategies

AU - Christensen, Neil

PY - 2005/1/1

Y1 - 2005/1/1

N2 - The cottontail rabbit papillomavirus (CRPV)/rabbit model has proven to be the most versatile preclinical model to test antiviral, immunopotentiating and immunotherapeutic strategies for papilloma-virus infections. We have utilized this model for many years and have recently observed significant improvements in the utility of the model. Improvements have included various techniques to infect rabbit skin sites with strains of wild-type and mutant CRPV DNA prepared using standard molecular biological procedures. A better understanding of the virus life cycle in vivo has been gained also from these studies such that we now have several defined strains of CRPV including i) antigenically diverse strains of CRPV, ii) mutant strains of CRPV with reduced growth rates, and iii) mutant strains of CRPV that demonstrate accelerated malignant progression rates. Collectively, these mutant genomes provide laboratories with a powerful pre-clinical model to assess a variety of antiviral therapies. Many of the treatments already tested in the CRPV/rabbit model have shown parallel efficacy against HPV infections in a clinical setting. Some of our recent experiences with the CRPV/rabbit model are outlined in this brief overview.

AB - The cottontail rabbit papillomavirus (CRPV)/rabbit model has proven to be the most versatile preclinical model to test antiviral, immunopotentiating and immunotherapeutic strategies for papilloma-virus infections. We have utilized this model for many years and have recently observed significant improvements in the utility of the model. Improvements have included various techniques to infect rabbit skin sites with strains of wild-type and mutant CRPV DNA prepared using standard molecular biological procedures. A better understanding of the virus life cycle in vivo has been gained also from these studies such that we now have several defined strains of CRPV including i) antigenically diverse strains of CRPV, ii) mutant strains of CRPV with reduced growth rates, and iii) mutant strains of CRPV that demonstrate accelerated malignant progression rates. Collectively, these mutant genomes provide laboratories with a powerful pre-clinical model to assess a variety of antiviral therapies. Many of the treatments already tested in the CRPV/rabbit model have shown parallel efficacy against HPV infections in a clinical setting. Some of our recent experiences with the CRPV/rabbit model are outlined in this brief overview.

UR - http://www.scopus.com/inward/record.url?scp=28544448601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28544448601&partnerID=8YFLogxK

U2 - 10.1177/095632020501600602

DO - 10.1177/095632020501600602

M3 - Review article

C2 - 16331841

AN - SCOPUS:28544448601

VL - 16

SP - 355

EP - 362

JO - Antiviral Chemistry and Chemotherapy

JF - Antiviral Chemistry and Chemotherapy

SN - 0956-3202

IS - 6

ER -